POL 6014

Drug Profile

POL 6014

Alternative Names: POL6014

Latest Information Update: 10 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polyphor
  • Class Macrocyclic compounds; Peptides; Small molecules
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alpha 1-antitrypsin deficiency; Bronchiectasis; Cystic fibrosis
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Oct 2016 Phase-I clinical trials in Bronchiectasis (Inhalation) in Switzerland (Polyphor pipeline, October 2016)
  • 25 Aug 2016 POl 6014 is still in preclinical development for Chronic obstructive pulmonary disease in Switzerland
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Switzerland (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top